Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-07-21

Study Completion Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The number of patients over 70 years old with cancer is increasing in France. This population is heterogenous: physiological functions, presence of co-morbidities, and autonomy can vary a lot between subjects of the same age. Physicians hesitate to treat them with optimal doses because they are afraid of the risk of toxicity in spite of the benefits of treatment. Fifty eight percent of gastric cancers are diagnosed in patients over the age of 70 in France. FOLFIRI (irinotecan, leucovorin and fluorouracil) chemotherapy appears to be a promising treatment for digestive cancer. It increases the level of response and survival without major toxicity. It becomes necessary to evaluate patients, to propose adapted treatments for their conditions.

The principal objectives are to demonstrate the efficacy of treatment, safety, survival and to find out if geriatric assessment data can help to better predict chemotherapy toxicity. The researchers plan to accrue 43 patients diagnosed with locally advanced or metastatic gastric cancer. They will receive FOLFIRI and 4 geriatric evaluations: before treatment, day 1 cycle 2, day 1 cycle 4 and at the end of chemotherapy. These evaluations include tests of cognitive functions (MMS), nutritional status (MNA), co-morbidity (CIRS-G), mobility (Get up and Go), activities (ADL; IADL), quality of life (QLQ-C30), depression (GDS-15) and Lachs-Balducci screening.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen

NCT03279289

Metastatic Colorectal Cancer

COMPLETED PHASE2

Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

NCT03081143

Advanced Gastric or EGJ Cancer

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies

NCT03043547

Cholangiocarcinoma Non-resectable Cholangiocarcinoma Metastatic Cholangiocarcinoma of the Gallbladder +1 more

COMPLETED PHASE2

Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer

NCT02138617

Colon Cancer

COMPLETED PHASE2

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

NCT00006115

Colorectal Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Irinotecan associated to fluorouracil and leucovorin

On D1, as a single 90-minute intravenous infusion diluted in 250 ml of saline (sodium chloride a 9 ‰), or isotonic glucose, at a dose of 180 mg/m2. Dosage adjustments are provided in case of severe toxicity.

Then 5FU/ folinic acid: 400 mg/m2 of 5-FU as an IV bolus followed by a continuous 2400 mg/m2 infusion over 46 hours with 400 mg/m2 of folinic acid or 200 mg/m2 of l-folinic acid as a 2-hour infusion before 5-FU administration.

Doses of 5-FU are adjusted according to clinical tolerance. Resume on D15 for 6 months

Group Type EXPERIMENTAL

Irinotecan associated to fluorouracil and leucovorin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Irinotecan associated to fluorouracil and leucovorin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 70 years of age or older
* Gastric cancer, locally advanced or metastatic
* No previous adjuvant treatment (surgery, radiotherapy, chemotherapy) in the last 6 months
* One measurable lesion
* ECOG \< 3
* Biology and biochemistry within normal limits
* Life expectancy \> 12 weeks

Exclusion Criteria

* Other palliative chemotherapy for this cancer
* Other cancer in the last 5 years
* Previous treatment with irinotecan
* Atropine treatment not possible
* Concomitant cancer therapy except bone radiotherapy
* Metastases to brain or meninges with symptoms
* Other severe pathology uncontrolled
* Problem of compliance

Minimum Eligible Age

70 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No